ASCO 2021
ASCO 2021
American Society of Clinical Oncology 2021 Annual Meeting
Advertisement
GU Oncology Now EditorsASCO 2021 | May 7, 2023
The implementation notably reduced the number of opioids that patients were prescribed.
Read More
Ariel JonesASCO 2021 | June 11, 2021
The risk of disease recurrence is high among patients with muscle-invasive urothelial carcinoma following radical surgery.
Ariel JonesASCO 2021 | November 30, 2022
In the study, a total of 117 men underwent 18F-DCFPyL-PET/CT.
Ariel JonesASCO 2021 | November 30, 2022
Staging with PSMA-PET/CT and response classification by Response Evaluation Criteria had prognostic value in prostate cancer.
Ariel JonesASCO 2021 | June 6, 2021
Assessing germline variants in patients who did and did not meet the NCCN 2019 PCa germline genetic testing criteria.
Ariel JonesASCO 2021 | June 6, 2021
Evaluating efficacy of a cancer peptide vaccine plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.
Ariel JonesASCO 2021 | September 19, 2022
Evaluating the effects of low household income on diagnosis, goals of care, and treatment choice in prostate cancer patients.
Ariel JonesASCO 2021 | June 4, 2021
Researchers evaluated patients with localized MIBC in clinical stages T2-4a who had no contraindications to immunotherapy.
Ariel JonesASCO 2021 | September 19, 2022
Racial disparities have been identified in prostate MRI and may affect outcomes for Black men with prostate cancer.
Ariel JonesASCO 2021 | June 4, 2021
A study evaluated trends in outpatient prostate cancer throughout the COVID-19 pandemic using a community-based registry.
Ariel JonesASCO 2021 | November 30, 2022
Is PSMA expression is a reliable predictor of response to Lu-177 PSMA in patients with castration-resistant prostate cancer?
Advertisement
Advertisement
Advertisement